News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Maral DerSarkissian, PhD

Articles by Maral DerSarkissian, PhD

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
October 21st 2016

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping

Grocery Assistance Benefit Linked to Fewer Diabetes Complications

ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM